Preclinical development of an innovative drug candidate, TOP-V122, for the treatment of lung fibrosis. (Innolink: 100.087 IP-LS)

Forschungsstelle

INNOSUISSE

Projektnummer

60677.1 IP-LS

Projekttitel

Preclinical development of an innovative drug candidate, TOP-V122, for the treatment of lung fibrosis. (Innolink: 100.087 IP-LS)

Projekttitel Englisch

Preclinical development of an innovative drug candidate, TOP-V122, for the treatment of lung fibrosis. (Innolink: 100.087 IP-LS)

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung		-	-
Abstract		-	-	-

Kategorie	Text
Kurzbeschreibung (Deutsch)	Preclinical development of an innovative drug candidate, TOP-V122, for the treatment of lung fibrosis. (Innolink: 100.087 IP-LS)
Kurzbeschreibung (Englisch)	Preclinical development of an innovative drug candidate, TOP-V122, for the treatment of lung fibrosis.
Abstract (Deutsch)	Idiopathic pulmonary fibrosis (IPF) is a form of restrictive interstitial lung disease (ILD) associated with extremely poor outcomes. With our approach based on a unique mode of action drug that restores cGMP levels, we aim to stop lung fibrosis progression and increase the survival rate.